Travere Therapeutics Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: travere.com
Recent Analyst Ratings for Travere Therapeutics Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | Overweight | Cantor Fitzgerald | |
| 10/21/2024 | $9.00 → $27.00 | Equal Weight → Overweight | Wells Fargo |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 9/9/2024 | $25.00 | Neutral → Buy | Guggenheim |
| 3/27/2024 | Buy → Neutral | Guggenheim | |
| 12/5/2023 | $7.00 → $10.00 | Neutral → Buy | Citigroup |
| 11/20/2023 | $7.00 | Neutral | Citigroup |
| 9/22/2023 | $24.00 → $8.00 | Overweight → Equal Weight | Wells Fargo |
| 9/21/2023 | Outperform → Mkt Perform | William Blair | |
| 9/6/2023 | $30.00 | Outperform | Evercore ISI |
Travere Therapeutics Inc. Press Releases
Fastest customizable press release news feed in the world
Travere Therapeutics to Report First Quarter 2025 Financial Results
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 31,100 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant da
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
Late-breaking oral presentation details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS Data presentations highlight SPARTAN Study results and real-world case studies of FILSPARI across different IgAN patient backgrounds Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation (NKF) Spring Clinical Meetings 2025, taking place April 10-13 in Boston, MA. The late-breaking oral presentation will feature new analyses from the Phase 3 DUPLEX Study of FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer. "We are excited to welcome Noah Rosenberg to the Verrica team as our new Chief Medical Officer," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. "As a highly accomplished drug development executive and physician, Noah's deep expertise will significantly help our efforts to establish YCANTH® as the new standard of care for the treatment of mo
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Additionally, the FDA notified the Company that REMS monitoring for embryo-fetal toxicity is no longer necessary; the Company plans to submit an amendment to the REMS sNDA currently under review for modification of liver monitoring SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced the Company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (F
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 77,200 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 41,200 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as induc
Travere Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will participate in the following upcoming investor conferences in March: TD Cowen 45th Annual Health Care ConferencePresenting on Monday, March 3, 2025, at 9:10 a.m. ET Leerink Partners Global Biopharma ConferencePresenting on Tuesday, March 11, 2025, at 9:20 a.m. ET Barclays 27th Annual Global Healthcare ConferenceWednesday, March 12, 2025 Jefferies Biotech on the Beach SummitWednesday, March 12, 2025 Live webcasts of the TD Cowen 45th Annual Health Care Conference and Leerink Partners Global Biopharma Conference presentations will be accessible on the Invest
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full year 2024 Net product sales totaled $74 million in 4Q 2024; $227 million for full year 2024 SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its fourth quarter and full year 2024 financial results and provided a corporate update. "Our strong execution in 2024 made it a remarkable year for Travere and the patients we serve. The ongoing commercial launch of FILSPARI outperformed benchmarks and the recent full approval has reinforced physicians
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics,
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 115,100 shares of its common stock to ten new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 79,100 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as indu
Travere Therapeutics Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Cantor Fitzgerald initiated coverage on Travere Therapeutics
Cantor Fitzgerald initiated coverage of Travere Therapeutics with a rating of Overweight
Travere Therapeutics upgraded by Wells Fargo with a new price target
Wells Fargo upgraded Travere Therapeutics from Equal Weight to Overweight and set a new price target of $27.00 from $9.00 previously
Scotiabank initiated coverage on Travere Therapeutics
Scotiabank initiated coverage of Travere Therapeutics with a rating of Sector Outperform
Travere Therapeutics upgraded by Guggenheim with a new price target
Guggenheim upgraded Travere Therapeutics from Neutral to Buy and set a new price target of $25.00
Travere Therapeutics downgraded by Guggenheim
Guggenheim downgraded Travere Therapeutics from Buy to Neutral
Travere Therapeutics upgraded by Citigroup with a new price target
Citigroup upgraded Travere Therapeutics from Neutral to Buy and set a new price target of $10.00 from $7.00 previously
Citigroup initiated coverage on Travere Therapeutics with a new price target
Citigroup initiated coverage of Travere Therapeutics with a rating of Neutral and set a new price target of $7.00
Travere Therapeutics downgraded by Wells Fargo with a new price target
Wells Fargo downgraded Travere Therapeutics from Overweight to Equal Weight and set a new price target of $8.00 from $24.00 previously
Travere Therapeutics downgraded by William Blair
William Blair downgraded Travere Therapeutics from Outperform to Mkt Perform
Evercore ISI resumed coverage on Travere Therapeutics with a new price target
Evercore ISI resumed coverage of Travere Therapeutics with a rating of Outperform and set a new price target of $30.00
Travere Therapeutics Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
CHIEF FINANCIAL OFFICER Cline Christopher R. sold $631 worth of shares (48 units at $13.14), decreasing direct ownership by 0.05% to 89,990 units (SEC Form 4)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
SENIOR VICE PRESIDENT, R&D Rote William E. converted options into 8,000 shares and sold $122,356 worth of shares (5,200 units at $23.53), increasing direct ownership by 3% to 98,519 units (SEC Form 4)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
SVP, GC & CORPORATE SECRETARY Reed Elizabeth E converted options into 8,000 shares and sold $188,240 worth of shares (8,000 units at $23.53) (SEC Form 4)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
SVP, CHIEF ACCOUNTING OFFICER Calvin Sandra exercised 45,000 shares at a strike of $16.63 and sold $1,356,100 worth of shares (54,244 units at $25.00), decreasing direct ownership by 15% to 54,410 units (SEC Form 4)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
CHIEF COMMERCIAL OFFICER Heerma Peter converted options into 8,000 shares and sold $137,276 worth of shares (5,642 units at $24.33), increasing direct ownership by 2% to 125,066 units (SEC Form 4)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
CHIEF EXECUTIVE OFFICER Dube Eric M sold $273,455 worth of shares (11,375 units at $24.04), decreasing direct ownership by 3% to 419,173 units (SEC Form 4)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
CHIEF MEDICAL OFFICER Inrig Jula converted options into 8,000 shares and sold $60,426 worth of shares (2,568 units at $23.53), increasing direct ownership by 6% to 89,602 units (SEC Form 4)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
Director Baynes Roy D. exercised 10,000 shares at a strike of $17.44 and sold $220,000 worth of shares (10,000 units at $22.00) (SEC Form 4)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
SENIOR VICE PRESIDENT, R&D Rote William E. sold $177,051 worth of shares (8,951 units at $19.78) and was granted 21,500 shares, increasing direct ownership by 15% to 95,719 units (SEC Form 4)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
CHIEF EXECUTIVE OFFICER Dube Eric M was granted 130,000 shares and sold $1,024,343 worth of shares (50,691 units at $20.21), increasing direct ownership by 23% to 430,548 units (SEC Form 4)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
Travere Therapeutics Inc. SEC Filings
SEC Form DEFA14A filed by Travere Therapeutics Inc.
DEFA14A - Travere Therapeutics, Inc. (0001438533) (Filer)
SEC Form DEF 14A filed by Travere Therapeutics Inc.
DEF 14A - Travere Therapeutics, Inc. (0001438533) (Filer)
Travere Therapeutics Inc. filed SEC Form 8-K: Other Events
8-K - Travere Therapeutics, Inc. (0001438533) (Filer)
SEC Form 10-K filed by Travere Therapeutics Inc.
10-K - Travere Therapeutics, Inc. (0001438533) (Filer)
Travere Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Travere Therapeutics, Inc. (0001438533) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by Travere Therapeutics Inc.
SCHEDULE 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
SEC Form 144 filed by Travere Therapeutics Inc.
144 - Travere Therapeutics, Inc. (0001438533) (Subject)
SEC Form 144 filed by Travere Therapeutics Inc.
144 - Travere Therapeutics, Inc. (0001438533) (Subject)
Travere Therapeutics Inc. filed SEC Form 8-K: Other Events
8-K - Travere Therapeutics, Inc. (0001438533) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by Travere Therapeutics Inc.
SCHEDULE 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
Travere Therapeutics Inc. Leadership Updates
Live Leadership Updates
Meissa Vaccines Appoints Frank Glavin Chief Executive Officer
Meissa Vaccines ("Meissa"), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, Ph.D., cofounder of Meissa, will serve as the Company's Chief Scientific Officer. "I am excited to welcome Frank to the Meissa leadership team," said Dr. Moore. "We are at an important stage in Meissa's growth, and Frank brings extensive, complementary experience in commercial planning, business developm
Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer
Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J
Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU). "We are excited to welcome Jula to the Travere Therapeutics
Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors
SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Ruth Williams-Brinkley to the Company's Board of Directors, effective immediately. Ms. Williams-Brinkley brings to Travere more than 35 years of executive leadership in care delivery and health plan operations. "On behalf of the Board of Directors, I am pleased to welcome Ruth to Travere," said Gary Lyons, chairman of the Travere Therapeutics Board of Directors. "She is a distinguished leader with extensive experience in the delivery of care and is an actively engaged and admired community leader. As we look to future potential commercial launches from our pipeline, Ru
Travere Therapeutics Inc. Financials
Live finance-specific insights
Travere Therapeutics to Report First Quarter 2025 Financial Results
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics,
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated for FSGS, a rare kidney disorder and leading cause of kidney failure sNDA submission to be based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the Company has completed its Type C meeting with the U.S. Food and Drug Administration (FDA) and plans to submit a supplemental New Drug Application (sN
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Travere Therapeutics Reports Third Quarter 2024 Financial Results
FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss potential sNDA submission for FILSPARI in FSGS sNDA requesting modification of liver monitoring for FILSPARI submitted to FDA Net product sales of FILSPARI totaled $35.6 million for the third quarter of 2024; 505 new PSFs received in the period Total revenue for the third quarter of 2024 was $62.9 million, including net product sales of $61.0 million SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today reported its third quarter 2024 financial result
Travere Therapeutics to Report Third Quarter 2024 Financial Results
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 8:30 a.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for li
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU). The voluntary enrollment pause enables the Company to work to address necessary process improvements in manufacturing scale-up to support commercial scale manufacturing as well as full enrollment in the HARMONY Study. Patients currently enrolled in pegtibatinase studies continue to receive study medication from small scale batches which are unaffected by the scale-up process. Currently enrolled patients will be able to continue on study medication as
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function preservation that accrued over two years Conversion to full approval based on results from the PROTECT Study, where FILSPARI delivered superior long-term kidney function preservation compared to the active comparator irbesartan in the only Phase 3 head-to-head trial conducted in IgAN As an oral, non-immunosuppressive and dual acting, once-daily medicine with superior long-term results vs. irbesartan, FILSPARI has the potential to become foundational care in IgAN
Ligand Reports Second Quarter 2024 Financial Results
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
Travere Therapeutics Reports Second Quarter 2024 Financial Results
Received 521 new patient start forms (PSFs) for FILSPARI® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch Net product sales of FILSPARI totaled $27.1 million for the second quarter of 2024 representing 37% growth over the previous quarter Company well-positioned for September 5, 2024 PDUFA target action date for conversion of the U.S. accelerated approval of FILSPARI to full approval in IgAN Total revenue for the second quarter of 2024 was $54.1 million, including net product sales of $52.2 million Cash, cash equivalents, and marketable securities, as of June 30, 2024, totaled $325.4 million SAN DIEGO, Au
Travere Therapeutics Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
SEC Form SC 13G filed by Travere Therapeutics Inc.
SC 13G - Travere Therapeutics, Inc. (0001438533) (Subject)
Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
SEC Form SC 13G filed by Travere Therapeutics Inc.
SC 13G - Travere Therapeutics, Inc. (0001438533) (Subject)
SEC Form SC 13G/A filed by Travere Therapeutics Inc. (Amendment)
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
SEC Form SC 13G/A filed by Travere Therapeutics Inc. (Amendment)
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)